{"slug":"pet-target","tag":"pet-target","variants":["pet-target"],"description":"No description yet","count":3,"kinds":{"target":3},"related":[{"slug":"theranostic","tag":"theranostic","shared":2},{"slug":"adc-target","tag":"adc-target","shared":1},{"slug":"stroma","tag":"stroma","shared":1}],"records":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/","tldr":"TROP2 is a surface glycoprotein present at high levels on most epithelial cancers (breast, lung, urothelial, gastric, pancreatic) and at low levels on normal tissue. It does not drive the cancer; it is a delivery address, used by the approved ADCs sacituzumab govitecan and datopotamab deruxtecan and by sacituzumab tirumotecan, with a TROP2 PET tracer in development to pick patients."},{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/","tldr":"A protein on prostate cancer cells that lets doctors both see the cancer on a PET scan and hit it with a radioactive drug."},{"id":"fap","kind":"target","name":"FAP","route":"/targets/fap/","tldr":"FAP (fibroblast activation protein) sits on the cancer-associated fibroblasts that scaffold more than 90% of epithelial cancers and is almost absent from normal adult tissue. FAPI PET tracers therefore light up tumours with high contrast, including pancreatic, gastric and low-grade cancers where FDG PET is weak, and FAP-targeted radioligands are in development."}]}